WebMay 9, 2024 · A high-level overview of BIND Therapeutics, Inc. (BIND) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. WebJan 31, 2024 · Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company ...
BIND Biosciences, Inc. Closes $11M Series C Financing Round
WebJun 22, 2015 · BIND Therapeutics, Inc. (BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced that Andrew Hirsch has been appointed president and chief executive officer of the Company. Mr. Hirsch had been serving in the role on an acting basis since March 2015. WebAug 2, 2016 · Delayed Nasdaq - 03:55:10 2016-08-02 pm EDT. 0.7500. USD. -4.46%. 2016. Bind Therapeutics : Determines Pfizer's $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND's Assets. PU. 2016. Bind Therapeutics : Determines Pfizer's $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND's Assets. maria taylor leather
BIND Therapeutics Presents Data Demonstrating Ability Of ... - BioSpace
WebJul 1, 2016 · BIND Therapeutics is a biotechnology company developing novel targeted therapeutics, primarily for the treatment of cancer. BIND’S product candidates are based on proprietary polymeric nanoparticles called ACCURINS®, which are engineered to target specific cells and tissues in the body at sites of disease. WebMar 15, 2016 · CAMBRIDGE, Mass., March 15, 2016. — BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable … WebBIND Therapeutics, Inc. and Macrophage Therapeutics recently announced they have entered into a research collaboration to engineer Accurins with the Manocept™ targeting platform that enables selective, … maria taylor in boots